Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), Indication (Influenza, Pneumococcal, Meningococcal, And Others), End Users (Pediatrics And Adults) - Forecast Till 2030
ID: MRFR/Pharma/2981-HCR | 115 Pages | Published By Rahul Gotadki on March 2023
Table of Contents
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Drivers
4.2 Restraints
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Supply Chain Analysis
6. Global Conjugates Vaccines Market, by Type
6.1 Haemophilus B
6.2 Monovalent
6.3 Multivalent
6.4 Others
7. Global Conjugates Vaccines Market, by Indication
7.1 Influenza
7.2 Pneumococcal
7.3 Meningococcal
7.4 Others
8. Global Conjugates Vaccines Market, by End User
8.1 Pediatrics
8.2 Adults
9. Global Conjugates Vaccines Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 UK
9.3.1.3 France
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Competitive Landscape
10.1 Cost of Products
10.2 Production Capacity of Major Players
11 Company Profile
11.1 GlaxoSmithKline plc.
11.1.1 Overview
11.1.2 Product/Business Segment Overview
11.1.3 Financial Updates
11.1.4 Key Developments
11.2 Merck & Co., Inc.
11.2.1 Overview
11.2.2 Product/Business Segment Overview
11.2.3 Financial Updates
11.2.4 Key Developments
11.3 Fablife
11.3.1 Overview
11.3.2 Product/Business Segment Overview
11.3.3 Financial Updates
11.3.4 Key Development
11.4 Pfizer Inc
11.4.1 Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Updates
11.4.4 Key Development
11.5 SutroVax Inc
11.5.1 Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financial Updates
11.5.4 Key Developments
11.6 Taj Pharmaceuticals Limited
11.6.1 Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financial Updates
11.6.4 Key Developments
11.7 Sanofi Pasteur SA
11.7.1 Overview
11.7.2 Product/Business Segment Overview
11.7.3 Financial Updates
11.7.4 Key Developments
11.8 Sinovac Biotech Ltd
11.8.1 Overview
11.8.2 Product/Business Segment Overview
11.8.3 Financial Updates
11.8.4 Key Developments
11.9 Bavarian Nordic
11.9.1 Overview
11.9.2 Product/Business Segment Overview
11.9.3 Financial Updates
11.9.4 Key Developments
11.9 Others
12 Conclusion
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Conjugates Vaccines Industry
13 Appendix
